Drug

Pertuzumab

Approved · EMA

ClassReceptor protein-tyrosine kinase erbB-2 inhibitorEmerging researchLate-stage developmentSteady momentum

Also known as Perjeta, Phesgo, rhuMAb2C4.

RxNorm1298944 ChEMBLCHEMBL2007641 ATCL01FD02UNIIK16AIQ8CTM

Research papers

Active clinical trials

ERBB2

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-07-31Results expected Q4 2026 · ClinicalTrials.gov

A Phase II Trial to Evaluate the Safety and Efficacy of HB1801 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Clinical trial2026-07-15Primary completion · ClinicalTrials.gov

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Clinical trial2026-07-10Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.

Clinical trial2026-07-07Results expected Q4 2026 · ClinicalTrials.gov

Approval: Poherdy (EMA)

Regulatory2026-04-23EMA

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Research2021-02-04Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.

Research2020-09-01ESMO open

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Research2017-06-05The New England journal of medicine

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Research2015-02-01The New England journal of medicine

Approval: Perjeta (EMA)

Regulatory2013-03-04EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Pertuzumab

Aliases & brands

PerjetaPhesgorhuMAb2C4

RxNorm CUI

1298944

ChEMBL ID

CHEMBL2007641

ATC codes

L01FD02

UNII

K16AIQ8CTM

Primary mechanism

Receptor protein-tyrosine kinase erbB-2 inhibitor

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Receptor tyrosine-protein kinase erbB-2

ERBB2 · P04626

INHIBITORReceptor protein-tyrosine kinase erbB-2 inhibitor

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2013-03-04

Latest approval

2026-04-23

Authorities

EMA

Total events

emaEuropean Medicines Agency· 2 events

2026-04-23Approval

Approval: Poherdy (EMA)

Indication: Early breast cancerPoherdy is indicated for use in combination with trastuzumab and chemotherapy in:- the neoadjuvant treatment of adult patients with HER2-positive, locally… Show full indication

Early breast cancerPoherdy is indicated for use in combination with trastuzumab and chemotherapy in:- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrenceMetastatic breast cancerPoherdy is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Evidence ↗

2013-03-04Approval

Approval: Perjeta (EMA)

Indication: Metastatic Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent… Show full indication

Metastatic Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Neoadjuvant Treatment of Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

196 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

196

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 196

Early Phase 12Phase 118Phase 1 / 217Phase 2100Phase 2 / 33Phase 350Phase 43Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Adjuvant Treatment of Breast Cancer

RecruitingPH IVKey trialSecond Affiliated Hospital, School of Medicine, Zhejiang Universityn=2,4132027

A Prospective, Open-label Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Neoadjuvant Treatment of Breast Cancer

RecruitingPH IVKey trialSecond Affiliated Hospital, School of Medicine, Zhejiang Universityn=1,5762027

A Phase IV, Multicenter, Open-Label, Single-Arm Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in First Line Treatment of Indian Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer

CompletedPH IVHoffmann-La Rochen=522018

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

RecruitingPH IIIKey trialAlliance for Clinical Trials in Oncologyn=1,5242037

The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study

RecruitingPH IIIAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)n=3762037

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer

CompletedPH IICity of Hope Medical Centern=632026

A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Patients With HER2-Positive Early Breast Cancer

CompletedPH IIIHoffmann-La Rochen=2002026

Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer

CompletedPH IIDana-Farber Cancer Instituten=232026

A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

CompletedPH IIIHoffmann-La Rochen=3462025

Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy

CompletedPH IIMemorial Sloan Kettering Cancer Centern=452025

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

CompletedPH IISWOG Cancer Research Networkn=2402025

Research activity

5 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20092021

Most influential

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

The New England journal of medicine · 2015 · 1,504 cites

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

The New England journal of medicine · 2017 · 970 cites

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

The oncologist · 2009 · 825 cites

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 264 cites

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.

ESMO open · 2020 · 140 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Breast Neoplasms4

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ertumaxomab

Acts on the same molecular target as Pertuzumab, with an overlapping disease area.

Shared target1 shared disease1 shared paper

Docetaxel

Studied across 2 of the same disease areas as Pertuzumab in the shared literature.

2 shared diseases1 shared paper

Everolimus

Studied across 2 of the same disease areas as Pertuzumab in the shared literature.

2 shared diseases1 shared paper

Sirolimus

Studied across 2 of the same disease areas as Pertuzumab in the shared literature.

2 shared diseases1 shared paper

Lapatinib

Studied across the same disease area as Pertuzumab in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.